Repligen
RGEN143.7701.08% ( -1.570 )
Repligen (RGEN)
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, an...
- Open
- 144.240
- High
- 149.730
- Low
- 143.580
- Prev. Close
- 145.340
- Volume
- 416.67K
- Turnover
- 60.79M
- Avg Price
- 145.902
- Bid/Ask Ratio
- --
- Amplitude
- 4.23%
- 52wk High
- 175.770
- Volume Ratio
- 0.65
- Turnover Ratio
- 0.78%
Repligen Analyst Rating
View MoreForecast & Rating
Jul 29, 2026Price forecast
$185.2128.85%
Forecast & RatingStrong buy
22analysts
- Strong buy68.18%
- Buy18.18%
- Hold13.64%
- Sell0.00%
- Strong sell0.00%
News
- TradingView · 19 hours ago
Repligen Corporation Stock 12‑Month Price Target Raised to $177.67, Implies 36% Upside
- MSN · 20 hours ago
Repligen soars 16% after blockbuster earnings, FY25 guidance upgrade
- Quartr · 1 day ago, 09:51 AM
RGEN: Raised 2026 guidance after strong Q2 growth, margin gains, and BioLife acquisition announcement
- benzinga_article · 1 day ago, 09:05 AM
Sherwin-Williams Posts Upbeat Q2 Earnings, Joins Itron, Armstrong World And Other Big Stocks Moving Higher On Tuesday
- Earnings Watch · 1 day ago, 06:15 AM
Repligen | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 204.13 M
- PUBT · 1 day ago, 06:14 AM
Repligen Q2 GAAP EPS drops 65.38% to $0.09; revenue rises 12% to $204 million
